Transcenta Holding Limited A Clinical Stage Biopharmaceutical Company With Fully-Integrated Capabilities In Discovery, Research, Development And Manufacturing Of Antibody-Based Therapeutics, Announces The Successful Dosing Of First Patient In China Phase Iia Study Of Tst001, A Claudin18.2 Monoclonal Antibody, Combined With Cisplatin And Gemcitabine For The First Line Treatment Of Systemic Treatment-Na
